Evaluation and Impact of Biosimilars: Perceptions from Payer and Health-System Experts

Our recent Primary Market Insights report summarizes insights from over 110 regional and national payer and health-system experts regarding biosimilar management strategy, the financial impact of biosimilars, and interchangeability. With input from vice presidents of pharmacy, pharmacy directors, clinical pharmacists, and purchasing/operations executives, the report examines how organizations are measuring biosimilar savings, planning for preferred products, covering Humira biosimilars, and reacting to price changes on long-acting insulin glargine products, and more.

Content on this site is proprietary to IPD Analytics. By receiving this sample you are agreeing to refrain from any unauthorized use, including uploading or inputting into AI tools or large language models for any purpose, is strictly prohibited.